Ernexa Therapeutics (ERNAW) Other Non Operating Income (2017 - 2026)
Ernexa Therapeutics' (ERNAW) quarterly Other Non Operating Income came in at $479000.0 in Q4 2025, down 97.87% YoY from $22.5 million in Q4 2024, and down 31.57% on a QoQ basis from $700000.0 in Q3 2025.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Other Non Operating Income (2017 - 2026) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 9 years of Other Non Operating Income data on file, last reported at $479000.0 in Q4 2025.
- Quarterly Other Non Operating Income fell 97.87% year-over-year to $479000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $921000.0 (up 1544.64% YoY) and the FY2025 annual result came in at $215000.0, up 207.14% from the prior year.
- Other Non Operating Income fell to $479000.0 in Q4 2025, from $700000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $22.5 million in Q4 2024 to a low of -$22.4 million in Q3 2024.
- A 5-year average of $25333.3 and a median of -$6500.0 in 2021 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 42571.7% in 2024, down 2239900.0% in 2024.
- Tracing ERNAW's Other Non Operating Income over 5 years: stood at $634000.0 in 2021, then slumped by 96.06% to $25000.0 in 2022, then slumped by 312.0% to -$53000.0 in 2023, then surged by 42571.7% to $22.5 million in 2024, then plunged by 97.87% to $479000.0 in 2025.
- The last three Other Non Operating Income figures came in at $479000.0 (Q4 2025), $700000.0 (Q3 2025), and -$123000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41,000.00 |
| Dec 31, 2025 | 66,000.00 |
| Sep 30, 2025 | 734,000.00 |
| Jun 30, 2025 | -123,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Sep 30, 2024 | -22.44 Mn |
| Dec 31, 2023 | -53,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -280,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | -10,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | -1.14 Mn |
| Dec 31, 2021 | 634,000.00 |
| Sep 30, 2021 | 290,000.00 |
| Jun 30, 2021 | -22,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Dec 31, 2020 | -11,518.00 |
| Sep 30, 2020 | -12,559.00 |